Home › NCT06798623
Anterior Cruciate Ligament (ACL) Reconstruction With Autologous Fat Pad Derived Mesenchymal Stem Cells
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Patients 18 years of age or older who are scheduled to undergo anterior cruciate ligament (ACL) reconstruction with bone-to-bone (BTB) patellar tendon autograft with the Principal Investigator (PI). * Receiving post-surgery physical therapy at a Houston Methodist physical therapy (PT) clinic. Exclusion Criteria: * Under 18 years of age * Prior surgery on affected knee * Diabetes * Root repair, inflammatory arthropathy, or any other concomitant procedure that cannot follow an accelerated PT protocol or any concomitant procedure that the PI deems exclusionary * Unable to attend physical therapy at Houston Methodist * Vulnerable populations * Immunocompromised patients such as those being treated for cancer, kidney failure, etc. * Heart disease (including systolic blood pressure \>180 mm Hg or heart failure) * Active infections * Non-English-speaking patients * Any known metal implants or allergy to contrast agents * Pregnancy (as part of standard of care, all female participants will be administered a urine pregnancy test prior to surgery. A negative result is required to proceed with surgery per SOC and thus, participate in the study) and those planning to become pregnant during the duration of the study * Any condition with known bleeding disorders, thrombus formation risk factors, or overlying wound and skin infections * Any condition in the opinion of the primary investigator that would compromise the integrity of the data collection or outcomes being assessed * Any other medical condition that in the opinion of the primary investigator would constitute a relative contraindication to study participation (e.g., Ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, SLE, scleroderma, polymyositis, Ehlers-Danlos syndrome, osteoporosis)
About the study
This study is designed as a prospective, open label, single arm pilot clinical study that will establish the safety and efficacy of a single injection of mesenchymal stromal cells in patients. Each subject will receive one intra-articular injection of autologous mesenchymal stromal cells derived from infrapatellar fat pad (FP-MSC) tissue samples collected from the subject during anterior cruciate ligament (ACL) reconstruction surgery.
What is being tested
- Autologous Mesenchymal Stromal Cells (biological)
Sponsor: The Methodist Hospital Research Institute · Participants: 15 · Started: Mar 24, 2026
Contact the study team
- Madison Bowden · Phone: 713-363-7390
- Haley Goble · Phone: 713-441-3930
Official record on ClinicalTrials.gov — NCT06798623
Locations in the U.S.
| Texas | Houston Methodist Hospital, Houston |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.